﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Pharmaceutical Sciences</JournalTitle>
      <Issn>1735-403X</Issn>
      <Volume>30</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month>10</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation</ArticleTitle>
    <FirstPage>444</FirstPage>
    <LastPage>455</LastPage>
    <ELocationID EIdType="doi">10.34172/PS.2024.9</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Maedeh</FirstName>
        <LastName>Yousefi</LastName>
        <Identifier Source="ORCID">https://orcid.org/0009-0004-1237-922X</Identifier>
      </Author>
      <Author>
        <FirstName>Hamed</FirstName>
        <LastName>Farzi-Khajeh</LastName>
      </Author>
      <Author>
        <FirstName>Mostafa</FirstName>
        <LastName>Akbarzadeh-Khiavi</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-1552-6537</Identifier>
      </Author>
      <Author>
        <FirstName>Azam</FirstName>
        <LastName>Safary</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-8997-2003</Identifier>
      </Author>
      <Author>
        <FirstName>Khosro</FirstName>
        <LastName>Adibkia</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-1053-5557</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/PS.2024.9</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>02</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>03</Month>
        <Day>13</Day>
      </PubDate>
    </History>
    <Abstract>Background: The therapeutic potential of epidermal growth factor receptor (EGFR) targeting in colorectal cancer (CRC) is hindered by the presence of KRAS codon 12 activating mutations, prevalent in approximately 25% of advanced CRC cases. This study investigates the role of reactive oxygen species (ROS) in conferring resistance to anti-EGFR monoclonal antibodies in KRAS mutant CRC cells, focusing on ROS-mediated apoptosis induction using cetuximab-PEGylated silica-coated magnetic nanoparticles (MNPs). Methods: MNPs were synthesized and surface-coated with silica, followed by functionalization and stabilization with polyethylene glycol (PEG). Cetuximab (Cet) was covalently conjugated to generate EMNP-PEG-Cet. Structural and compositional analyses were performed using scanning electron microscopy (SEM), dynamic light scattering (DLS), UV-vis spectroscopy, and Fourier transform infrared (FTIR) analysis. Apoptosis induction, chromatin condensation, and ROS production were evaluated in KRAS mutant SW-480 CRC cells. Results: Successful synthesis of EMNP-PEG-Cet was confirmed, revealing a particle size of 67 nm and a surface charge of -8.3 mV. The conjugate exhibited significant cytotoxicity against CRC cells, with notable apoptosis induction and ROS generation in EGFR-positive/KRAS mutant SW-480 cells, surpassing the effects observed with bare Cet and EMNP-PEG controls. The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-related protein 1 (Nrf2-Kaep1) gene expression analysis by real-time PCR showed that cells treated with EMNP-PEG-Cet exhibited a noteworthy decrease in Nrf2 expression and a simultaneous increase in Keap1 expression compared to those treated with free Cet. Conclusion: These findings highlight the potential of ROS-mediated apoptosis induction to enhance the cytotoxicity of Cet in EGFR-positive/KRAS mutant CRC cells, offering new avenues for overcoming drug resistance mechanisms in metastatic CRC.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KRAS mutant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Magnetic nanoparticles</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PEGylation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Reactive oxygen species</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>